Drugs / Drugs and anti-CD19 CAR transduced T cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03191773 Background | Jun 2017 → Dec 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Second Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drugs and anti-CD19 CAR transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03191773 ↗ |
| Route | Intravenous | “Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.” NCT03191773 ↗ |